You are here

AdvaMed COVID Testing Supply Registry

About the National COVID-19 Supply Registry

AdvaMed has been working closely with the White House, HHS, FDA, FEMA and other key government agencies to ensure the continued supply of diagnostics tests, as well as other vital medical equipment such as PPE and ventilators, in the fight against the COVID-19 pandemic.

To further assist state and federal governments in their pandemic responses, AdvaMed has created a comprehensive, national COVID-19 diagnostic supply registry which compiles information from diagnostic companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry.

AdvaMed’s registry aims to help streamline communications and data sharing between diagnostic companies and federal and state governments as well as standardize test supply reporting. It also facilitates collaboration with laboratories and other public health stakeholders to optimize access to all platforms of COVID-19 testing so that any potential shortages are identified and addressed quickly.

Learn More

Topline Data As of September 18, 2020

The registry’s latest dataset shows that since the beginning of the pandemic, over 160 million molecular COVID-19 tests have been manufactured and shipped nationwide.

Manufacturers have increased Molecular test production from ~600,0001 U.S. shipments per day at the start of May to about 1.2 million shipments per day1 by September 12th. 

  • The over 160M cumulative molecular COVID-19 tests shipped nationwide since March 2020 by the 13 Registry participants include ~115M commercial tests and ~45M extraction reagents​.
    • Abbott
    • BD 
    • BioMérieux 
    • Bio-Rad 
    • Beckman Coulter 
    • Cepheid 
    • Hologic 
    • Ortho Clinical Diagnostics 
    • QIAGEN 
    • Roche Diagnostics 
    • Sekisui Diagnostics 
    • Siemens Healthineers 
    • Thermo Fisher Scientific 
       
  • Per public sources, daily molecular tests run have decreased ~9% compared to the previous week, down to an average of ~755,0002 per day last week.
     
  • High-quality serology testing, authorized by FDA, remains available at scale with industry capacity to manufacture 100 million tests per month.  
     
  • Registry participants are bringing antigen testing to the market with significant manufacturing capacity.

1 Averaged over latest 4 weeks to account for fluctuations in buying cycle
2 Averaged over the week to account for fluctuations by day of the week

Weekly Reporting

The registry provides weekly state- and national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in the U.S.